Wayne Richey, MD
Family Medicine · Trion, GANPI 1073508115
Payments from drug & device makers
Across 300 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$469
- AstraZeneca$430
- Pfizer$356
- GSK$321
- Boston Scientific$290
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,012100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 103 | $1,271 |
| Novo Nordisk | 26 | $469 |
| AstraZeneca | 23 | $430 |
| Pfizer | 20 | $356 |
| GSK | 21 | $321 |
| Boston Scientific | 5 | $290 |
| Lilly USA, LLC | 15 | $228 |
| Exact Sciences | 11 | $202 |
| Abbott | 9 | $154 |
| Sanofi-aventis U.S. LLC | 7 | $136 |
| Phathom Pharmaceuticals, Inc. | 7 | $132 |
| Astellas Pharma US Inc | 5 | $108 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $101 |
| Xeris Pharmaceuticals, Inc. | 5 | $97 |
| Dexcom, Inc. | 3 | $88 |
| Mylan Specialty L.p. | 4 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $69 |
| Novartis | 3 | $68 |
| Merck | 4 | $62 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Lundbeck LLC | 2 | $54 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Shire North American Group Inc | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Almatica Pharma LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$152
How this compares
$5,012 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 162 | $173,757 |
| EliquisApixaban | 182 | $167,380 |
| TrulicityDulaglutide | 85 | $153,382 |
| JardianceEmpagliflozin | 113 | $87,396 |
| JanuviaSitagliptin Phosphate | 74 | $55,342 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $51,471 |
| FarxigaDapagliflozin Propanediol | 38 | $40,957 |
| MounjaroTirzepatide | 36 | $37,570 |
| XareltoRivaroxaban | 25 | $31,520 |
| Spiriva HandihalerTiotropium Bromide | 32 | $26,945 |
| CaplytaLumateperone Tosylate | 17 | $26,916 |
| RybelsusSemaglutide | 13 | $25,764 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $24,065 |
| EntrestoSacubitril/Valsartan | 28 | $20,091 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $18,723 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $469 | $199,520175 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $228 | $190,952121 claims |
| PfizerEliquis, Premarin | $356 | $175,277206 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $321 | $76,10192 claims |
| MerckJanuvia, Janumet | $62 | $73,23185 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $430 | $65,02267 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $101 | $26,91617 claims |
| NovartisEntresto | $68 | $20,09128 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $41 | $15,53026 claims |
| Astellas Pharma US IncMyrbetriq | $108 | $9,66516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Trion
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.